Men with prostate cancer are three times more likely to die from it if they have a particular genetic mutation.
Up to one in five patients may have a genetic quirk which worsens their chances of survival and makes them more likely to relapse.
Most men with prostate cancer do not die from it, but scientists sought to find those with advanced cancer who were at greatest risk. In a study of 429 men at this stage of cancer, they found those with a mutated gene called RB1 in their tumour were 3.3 times more likely to die.
Oxford Biodynamics PLC (LON:OBD) was spun out from Oxford University in June 2007 with the aim of translating fundamental scientific advances into a commercialised platform technology and a new generation of biomarkers for cancer and other diseases including ALS.